Vor Biopharma Inc (VOR NASDAQ) stock market data APIs
$19.9159
0.3(1.5%)
as of July 7, 2026
Try our APIs with
free plan!
Vor Biopharma Inc Financial Data Overview
Price chart is built with
Anychart
Vor Biopharma Inc., a clinical-stage biopharmaceutical company, focuses on the development of a novel therapy in the treatment of autoimmune diseases. The company offers telitacicept, a novel fusion protein for the treatment of generalized myasthenia gravis, systemic lupus erythematosus, and rheumatoid arthritis, as well as Sjögren's disease and IgA nephrapathy. It has a license agreement with RemeGen Co., Ltd. for the exploitation, development, and commercialization of telitacicpet and related products. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.
Prev. Close
19.9159
Open
20.2193
High
20.6572
Low
19.3541
52 wk Range
6.5-60.4
Market Cap
1 089 M
Shares Outstanding
54 186 K
EPS
-0.726
Beta
1.695
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Vor Biopharma Inc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Vor Biopharma Inc data using free add-ons & libraries
Get Vor Biopharma Inc Fundamental Data
Vor Biopharma Inc Fundamental data includes:
- Net Revenue:
- EBITDA: -341 715 008
- Earnings Per Share: -70
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2026-05-14
- EPS/Forecast: -0.7825
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Vor Biopharma Inc News
New
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
BOSTON, July 02, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that, on July 1, 2026, the ...
Telitacicept Receives NMPA Approval for the Treatment of Sjögren’s Disease in China
Vor Biopharma First regulatory approval for Sjögren's disease (SjD) First and only approved therapy for SjD in China Approval based on positive Phase 3 results generated by collaborator RemeGen de...
Telitacicept Receives NMPA Conditional Approval for the Treatment of IgA Nephropathy in China
Vor Biopharma First and only approved BAFF/APRIL-targeting therapy for IgA nephropathy (IgAN) Approval based on positive interim Phase 3 TELIGAN results generated by collaborator RemeGen and recentl...
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
BOSTON, Mass., June 01, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that, on June 1, 202...
Get Vor Biopharma Inc fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
